期刊
ADVANCES IN RHEUMATOLOGY
卷 61, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s42358-021-00228-x
关键词
-
类别
资金
- Brazilian Society of Rheumatology
Rheumatoid arthritis is a chronic autoimmune systemic inflammatory disease that affects patients' quality of life. New therapeutic targets like Janus kinases have emerged, with JAK inhibitors gaining importance as a highly effective treatment for RA.
Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据